Total amount: € 0,00
HOW TO ORDER
GAZZETTA MEDICA ITALIANA ARCHIVIO PER LE SCIENZE MEDICHE
A Journal on Internal Medicine and Pharmacology
Indexed/Abstracted in: BIOSIS Previews, EMBASE, Scopus, Emerging Sources Citation Index
Gazzetta Medica Italiana Archivio per le Scienze Mediche 2004 October;163(5):139-44
Ca 125 blood levels and heart failure: a strong relationship
Varvarigos N. 1, Kappas A. 1, Avramopoulou T. H. 1, Kalogeropoulou K. 2, Papaioannou H. A. 1, Dimakopoulos N. 2, Migdalis I. N. 3, Galanis C. 1, Mortzos G. 2
1 Department of Cardiology, NIMTS Hospital, Athens, Greece;
2 Department of Nuclear, NIMTS Hospital, Athens, Greece;
3 Second Department of Internal Medicine, NIMTS Hospital, Athens, Greece
Aim. CA 125, a widely used tumor marker for ovarian cancer was reported to be also elevated in some benign conditions. Recently, it has been observed to be a successful prognostic factor in heart failure patients pre and postheart transplantation. Aim of this study was to find if there is a relationship between CA 125 blood levels and heart functional status.
Methods. CA 125 blood levels were determined in 72 patients (49 men and 23 women, aged 72,4±10.85 years) with heart failure. CA 125 normal values were 0-35 U/ml. The results were grouped according to the clinical status (New York Heart Association Classificatio, NYHA) and the ejection fraction of the patients, as was determined by both radionuclide ventriculography and cardiac ultrasound, and analyzed by Pearson Correlation test, ANOVA and χ2 test of SPSS 8.0 statistical program. The female patients with elevated CA 125 levels were examined for ovarian cancer.
Results. CA 125 levels according to NYHA were the following: stage 1: 6.4±5.8 (14 patients), stage 2: 37.4±32.69 (22 patients), stage 3: 108.2±40.27 (21 patients) and stage 4: 303.9± 270.9 (15 patients). There were 23 female patients with elevated CA 125 blood levels which underwent ultrasonography or CT-scan and in all 23 patients ovarian cancer was excluded. Statistical analysis revealed a significant relationship between CA 125 and NYHA stage (p: 0.012). Significant negative correlation was also found between CA 125 and radionuclide ejection fraction, with p-value: 0.002 and Pearson correlation coefficient: -0.642 as well as between CA 125 and echo ejection fraction with p-value: 0.004 and Pearson correlation coefficient: -0.582 and fractional shortening (p-value: 0.006 and Pearson correlation coefficient: -0.525).
Conclusion. CA 125, besides an excellent ovarian cancer marker, is also a marker of heart functional status. The determination of CA 125 blood levels may be a useful tool in heart failure management.